These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1372 related articles for article (PubMed ID: 28281173)
1. Glioma Subclassifications and Their Clinical Significance. Chen R; Smith-Cohn M; Cohen AL; Colman H Neurotherapeutics; 2017 Apr; 14(2):284-297. PubMed ID: 28281173 [TBL] [Abstract][Full Text] [Related]
2. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
3. Anaplastic gliomas in adults: an update. Izquierdo C; Joubert B; Ducray F Curr Opin Oncol; 2017 Nov; 29(6):434-442. PubMed ID: 28901965 [TBL] [Abstract][Full Text] [Related]
4. The Role of Molecular Diagnostics in the Management of Patients with Gliomas. Wirsching HG; Weller M Curr Treat Options Oncol; 2016 Oct; 17(10):51. PubMed ID: 27501915 [TBL] [Abstract][Full Text] [Related]
5. Clinical impact of revisions to the WHO classification of diffuse gliomas and associated future problems. Sonoda Y Int J Clin Oncol; 2020 Jun; 25(6):1004-1009. PubMed ID: 32020379 [TBL] [Abstract][Full Text] [Related]
6. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV. McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682 [TBL] [Abstract][Full Text] [Related]
7. Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. Yang P; Cai J; Yan W; Zhang W; Wang Y; Chen B; Li G; Li S; Wu C; Yao K; Li W; Peng X; You Y; Chen L; Jiang C; Qiu X; Jiang T; Neuro Oncol; 2016 Aug; 18(8):1099-108. PubMed ID: 26957363 [TBL] [Abstract][Full Text] [Related]
8. Treatment of anaplastic glioma. Wick W; Wiestler B; Platten M Cancer Treat Res; 2015; 163():89-101. PubMed ID: 25468227 [TBL] [Abstract][Full Text] [Related]
9. Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Erdem-Eraslan L; Gravendeel LA; de Rooi J; Eilers PH; Idbaih A; Spliet WG; den Dunnen WF; Teepen JL; Wesseling P; Sillevis Smitt PA; Kros JM; Gorlia T; van den Bent MJ; French PJ J Clin Oncol; 2013 Jan; 31(3):328-36. PubMed ID: 23269986 [TBL] [Abstract][Full Text] [Related]
11. Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. Dubbink HJ; Atmodimedjo PN; Kros JM; French PJ; Sanson M; Idbaih A; Wesseling P; Enting R; Spliet W; Tijssen C; Dinjens WN; Gorlia T; van den Bent MJ Neuro Oncol; 2016 Mar; 18(3):388-400. PubMed ID: 26354927 [TBL] [Abstract][Full Text] [Related]
12. Anaplastic glioma: current treatment and management. Le Rhun E; Taillibert S; Chamberlain MC Expert Rev Neurother; 2015 Jun; 15(6):601-20. PubMed ID: 25936680 [TBL] [Abstract][Full Text] [Related]
13. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Boots-Sprenger SH; Sijben A; Rijntjes J; Tops BB; Idema AJ; Rivera AL; Bleeker FE; Gijtenbeek AM; Diefes K; Heathcock L; Aldape KD; Jeuken JW; Wesseling P Mod Pathol; 2013 Jul; 26(7):922-9. PubMed ID: 23429602 [TBL] [Abstract][Full Text] [Related]
14. Predictive biomarkers in adult gliomas: the present and the future. Thomas L; Di Stefano AL; Ducray F Curr Opin Oncol; 2013 Nov; 25(6):689-94. PubMed ID: 24076583 [TBL] [Abstract][Full Text] [Related]
15. The 2016 revision of the WHO Classification of Central Nervous System Tumours: retrospective application to a cohort of diffuse gliomas. Rogers TW; Toor G; Drummond K; Love C; Field K; Asher R; Tsui A; Buckland M; Gonzales M J Neurooncol; 2018 Mar; 137(1):181-189. PubMed ID: 29218432 [TBL] [Abstract][Full Text] [Related]
16. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma. Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640 [TBL] [Abstract][Full Text] [Related]